Oxidative analysis, clinical-laboratory parameters, and quality of life in treatment associated with ozone therapy in female dogs with mammary tumors.

Abstract

Canine mammary tumors (CMT) primarily affect female dogs. Their high prevalence, chronic nature, and potential aggressiveness often lead to metastasis, systemic disease, and death despite the use of conventional treatment based on surgery and chemotherapy. There is a need for complementary, accessible, and low-cost therapies to improve the perioperative care of these canine patients. In this context, this study aimed to evaluate the effectiveness of ozonated autohemotherapy as an integrative therapy by analyzing markers of oxidative balance, clinical-laboratory parameters, and quality of life of dogs with CMT. Forty-nine dogs were examined and allocated into study groups: dogs treated with only mastectomy (GM; n&#xa0;=&#xa0;11), mastectomy with ozonated autohemotherapy (GM-AHmO; n&#xa0;=&#xa0;13), and mastectomy with non-ozonated autohemotherapy (GM-AHm; n&#xa0;=&#xa0;12); a fourth group contained negative control healthy dogs (GH; n&#xa0;=&#xa0;13). Assessment of clinical, hematological (erythrocytes, platelets, lymphocytes, urea, creatinine, ALT, ALP), oxidative markers (TAC and MDA), and quality-of-life was performed at five-day points, D0, D1, D2, D3, and D4. The GM-AHmOshowed progressive improvement in quality-of-life scores (from 26.4 to 32; p&#xa0;<&#xa0;0.001), increased total antioxidant capacity (TAC: 13.1 to 16.1; p&#xa0;=&#xa0;0.003), and decreased malondialdehyde levels (MDA: 438 to 150.5; p&#xa0;=&#xa0;0.002) from D0 to D4. Significant reductions were observed in creatinine (p&#xa0;=&#xa0;0.006), ALT (p&#xa0;=&#xa0;0.001), and ALP (p&#xa0;=&#xa0;0.043) in GM-AHmO, indicating improvement in renal and hepatic profiles. Additionally, a significant decrease in creatinine levels was noted at D4 in GM-AHmO(p&#xa0;=&#xa0;0.017). Comparative data between groups and time points showed that ozonated autohemotherapy enhanced antioxidant responses, reduced oxidative stress, improved renal and hepatic functions, and, importantly, improved CMT patients' life quality. As a preliminary investigation, this study indicates that AHmOis a beneficial approach as a complementary method to enhance the well-being of dogs with CMTs undergoing mastectomy.